Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 20/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16445145 | 0.93 | CFTR (0.74) | CFTR | |
| SCHEMBL16451417 | 0.86 | CFTR (0.80) | CFTR | |
| SCHEMBL16445078 | 0.85 | CFTR (1.00) | CFTR | |
| SCHEMBL20454534 | 0.83 | CFTR (0.76) | CFTR | |
| SCHEMBL16451338 | 0.83 | CFTR (0.76) | CFTR | |
| SCHEMBL16444981 | 0.83 | CFTR (1.00) | CFTR | |
| SCHEMBL16445247 | 0.83 | CFTR (0.78) | CFTR | |
| SCHEMBL16445788 | 0.83 | CFTR (0.78) | CFTR | |
| SCHEMBL16445374 | 0.82 | CFTR (0.71) | CFTR | |
| SCHEMBL19879828 | 0.82 | CFTR (0.74) | CFTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10568867-B2 | Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis | GALAPAGOS NV (BE) | 2020-02-25 | — | — | US | disclosed |
| US-20180221334-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS | GILEAD SCIENCES, INC. | 2018-08-09 | — | — | US | disclosed |
| US-9895347-B2 | Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis | GALAPAGOS NV (BE) | 2018-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10568867-B2 | Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis | CFTR, ABCB11, PKD1 | CFTR 1/4885 |
| US-20180221334-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, ABCB11, ABCC5 | CFTR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.